arise that may affect their willingness to continue participation. This ensures protection of participants’ rights, safety, and autonomy, in compliance with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.

Scope

This SOP applies to all investigators, sub-investigators, study coordinators, and regulatory personnel involved in obtaining and documenting re-consent from participants in ongoing clinical trials. It covers situations such as safety updates, protocol amendments, administrative corrections, and regulatory-mandated re-consent.

Responsibilities

• Principal Investigator (PI): Ensures participants are re-consented when required and that accurate documentation is maintained.
• Study Coordinator/Sub-Investigator: Assists in conducting the re-consent process and maintains updated participant records.
• Regulatory Affairs Manager: Ensures all re-consent forms are EC/IRB-approved before implementation.
• Quality Assurance Officer: Audits re-consent records for compliance.
• Head of Clinical Research: Oversees re-consent process implementation.

Accountability

The Principal Investigator is accountable for ensuring re-consent procedures are carried out correctly and in compliance with applicable regulations. Failure to re-consent participants in a timely and documented manner may lead to ethical and regulatory violations.

Procedure

1. Identification of Need for Re-consent
Assess whether new information (e.g., safety updates, protocol amendments, revised study design) necessitates re-consent.
Determine the type of re-consent required (substantial or administrative).
Seek EC/IRB approval for the updated Informed Consent Form (ICF) prior to implementation.

2. Preparation of Re-consent Forms
Draft revised ICFs incorporating new information.
Translate into local languages as required.
Submit updated versions to EC/IRB for review and approval.

3. Conducting the Re-consent Process
Provide participants sufficient time to review revised ICF.
Explain the new information clearly, addressing risks, benefits, and participant rights.
Encourage participants to ask questions and confirm their understanding.
Obtain participant signature (or legally authorized representative), date, and witness signature (if required).
Provide a copy of signed ICF to the participant.

4. Documentation and Record Keeping
File signed re-consent ICFs in the site master file and participant trial records.
Record re-consent activity in the Consent Documentation Log.
Maintain version control of all ICFs used.

5. Re-consent for Vulnerable Populations
For minors or legally incapacitated subjects, ensure consent is obtained from legal guardian and assent (if appropriate).
For illiterate participants, ensure presence of impartial witness during re-consent.

6. Electronic Re-consent (eConsent)
Use validated systems for eConsent compliant with FDA 21 CFR Part 11, EMA, and ICH GCP.
Ensure identity verification and maintain secure audit trails.

7. Archiving
Store all re-consent forms securely with restricted access.
Retain records for minimum of 5 years post trial completion or as per local regulations.

Abbreviations

• SOP: Standard Operating Procedure
• ICF: Informed Consent Form
• PI: Principal Investigator
• EC: Ethics Committee
• IRB: Institutional Review Board
• QA: Quality Assurance
• eConsent: Electronic Consent

Documents

1. Re-consent Form Template (Annexure-1)
2. Re-consent Documentation Log (Annexure-2)
3. EC/IRB Re-consent Approval Letter (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA 21 CFR Part 50 – Informed Consent
• EMA Guidance on Re-consent Requirements
• WHO GCP Guidelines
• CDSCO Clinical Trial Rules, 2019

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Clinical Research Coordinator
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Principal Investigator

Annexures

Annexure-1: Re-consent Form Template

Section	Description
Protocol Number	[Insert Protocol]
Reason for Re-consent	[Safety update/Protocol amendment/etc.]
Participant Statement	I have read and understood the revised information

Annexure-2: Re-consent Documentation Log

Date	Participant ID	ICF Version	Investigator	Witness (if applicable)
10/09/2025	PAT-010	V2.0	Dr. Meera Joshi	Ravi Kumar

Annexure-3: EC/IRB Re-consent Approval Letter

Date	EC/IRB Name	Protocol No.	Approval Status	Remarks
08/09/2025	City EC	CTP-2025-07	Approved	Revised safety section included

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Research

For more SOPs visit: Pharma SOP